Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical study
In conclusion, heterologous boosting with CORBEVAX™ substantially enhanced humoral and cellular immunity against SARS-CoV-2 VoCs while being well tolerated.
Authors
- Anil Kumar Pandey (ORCID: https://orcid.org/0000-0002-0078-4656)
- SubbaReddy Gunneri
- Subhash Thuluva (ORCID: https://orcid.org/0000-0002-9099-420X)
- Shiva Narang (ORCID: https://orcid.org/0000-0002-6480-2091)
- Akshay Binayke (ORCID: https://orcid.org/0000-0002-9808-9036)
- Rammohan Reddy Mogulla (ORCID: https://orcid.org/0000-0001-6638-7701)
- Chirag Dhar (ORCID: https://orcid.org/0000-0002-7351-485X)
- Vikram Paradkar (ORCID: https://orcid.org/0000-0001-9500-7237)
- Aymaan Zaheer
- Amit Awasthi (ORCID: https://orcid.org/0000-0002-2563-1971)
- Vijay Yerroju (ORCID: https://orcid.org/0000-0003-4192-3760)
- Kamal Thammireddy (ORCID: https://orcid.org/0009-0007-7614-4026)
- Priya Reddy
- Siddalingaiah Ningaiah (ORCID: https://orcid.org/0009-0006-6116-4959)
- Chitta Sitaram Anjaneylu
Institutions
- Translational Health Science and Technology Institute (IN)
- Guru Teg Bahadur Hospital (IN)
- Biological E (India) (IN)
- Asian Institute of Gastroenterology (IN)
- St. Theresa’s Multi-Speciality Hospital (IN)
- ESIC Hospital (IN)
- Bharati Vidyapeeth (Deemed to be University) (IN)
Publication Details
- Journal
- IJID Regions
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1016/j.ijregi.2025.100786
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00